Percutaneous Cryoablation of T1A Renal Cell Carcinoma: Functional Outcomes and Residual Disease Management
Abstract
Objective: This retrospective cohort study evaluated the efficacy, safety, and functional outcomes of percutaneous cryoablation in T1a renal cell carcinoma (RCC), with an emphasis on residual disease management and radiological follow-up.
Materials and Methods: Thirteen patients with 15 T1a RCC lesions treated with percutaneous cryoablation between September 2023 and June 2024 were retrospectively analyzed. Clinical and follow-up data were collected. All procedures were performed under CT and US guidance using a standardized double freeze–thaw protocol. Follow-up included renal function assessment and radiological imaging with MRI or CT at the 3rd month, 6th month, and 1 year.
Results: The study included 11 males (84.6%) and 2 females, with a median age of 62 years (range, 50-71 years). The median tumor diameter was 22 mm, and the PADUA score was 8. The median number of cryoablation probes used per procedure was 2 (range, 1-3), and the median procedural time was 60 minutes. Complete ablation was achieved in most patients; however, residual disease was detected in three patients during follow-up. Among those with residual disease, one underwent repeat cryoablation, one underwent surgery, and one underwent active surveillance. Complications were minor, including a single hematoma and one intracystic hemorrhage, both of which were asymptomatic. Renal function was preserved throughout the follow-up period, including in solitary kidney patients, with no clinically significant eGFR decline.
Conclusion: Percutaneous cryoablation achieved local tumor control with preservation of renal function and a low complication rate during follow-up in patients with T1a RCC.
Keywords
References
- Woon D, Qin S, Al-Khanaty A, Perera M, Lawrentschuk N. Imaging in renal cell carcinoma detection. Diagnostics 2024;14(18):2105. google scholar
- Saad AM, Gad MM, Al-Husseini MJ, Ruhban IA, Sonbol MB, Ho TH. Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER- based study. Clin Genitourin Cancer 2019;17(1):46-57.e5. google scholar
- Bellin MF, Valente C, Bekdache O, Maxwell F, Balasa C, Savignac A, et al. Update on renal cell carcinoma diagnosis with novel imaging approaches. Cancers 2024;16(10):1926. google scholar
- Wang L, Guer M, Puri D, Liu F, Dhanji S, Meagher MF, et al. Characteristics and outcomes of T1a renal cell carcinoma presenting with metastasis. Cancers 2025;17(3):364. google scholar
- Young M, Jackson-Spence F, Beltran L, Day E, Suarez C, Bex A, et al. Renal cell carcinoma. Lancet 2024;404(10451):476-91. google scholar
- Bex A, Ghanem YA, Albiges L, Bonn S, Campi R, Capitanio U, et al. European Association of Urology guidelines on renal cell carcinoma: The 2025 update. Eur Urol 2025;87(6):683-96. google scholar
- Simmons MN, Fergany AF, Campbell SC. Effect of parenchymal volume preservation on kidney function after partial nephrectomy. J Urol 2011;186(2):405-10. google scholar
- Bertolotti L, Bazzocchi MV, Iemma E, Pagnini F, Ziglioli F, Maestroni U, et al. Radiofrequency ablation, cryoablation, and microwave ablation for the treatment of small renal masses: efficacy and complications. Diagnostics 2023;13(3):388. google scholar
Details
Primary Language
English
Subjects
Oncologic Surgery, Radiology and Organ Imaging
Journal Section
Research Article
Authors
İlker Teke
0009-0002-2294-4267
Türkiye
Celal Caner Ercan
0000-0003-2922-5847
Türkiye
Selçuk Erdem
0000-0002-3514-1394
Türkiye
Mehmet Öner Şanlı
0000-0001-5801-6898
Türkiye
Faruk Özcan
0000-0001-7544-6638
Türkiye
Bulent Acunas
0000-0003-4695-6043
Türkiye
Publication Date
August 14, 2026
Submission Date
January 14, 2026
Acceptance Date
May 11, 2026
Published in Issue
Year 2026 Volume: 89 Number: 3